Inhaled antibiotics for treatment of adults with non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis

2021 ◽  
Author(s):  
Sofia Tejada ◽  
Laura Campogiani ◽  
Candela Solé-Lleonart ◽  
Aroa Gómez ◽  
Miguel Gallego ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cystic Fibrosis ◽  
Meta Analysis ◽  
Inhaled Antibiotics

scholarly journals Prevention of exacerbations in patients with stable non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis of pharmacological and non-pharmacological therapies

2018 ◽  
Vol 23 (3) ◽  
pp. 96-103 ◽  
Author(s):  
Abd Moain Abu Dabrh ◽  
Adam T Hill ◽  
Claudia C Dobler ◽  
Noor Asi ◽  
Wigdan H Farah ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Cystic Fibrosis ◽  
Meta Analysis ◽  
Moderate Quality ◽  
Number Of Patients ◽  
Inhaled Antibiotics ◽  
Quality Evidence

BackgroundSeveral pharmacological and non-pharmacological therapies are used to treat stable bronchiectasis of non-cystic fibrosis (CF) aetiology.ObjectiveWe conducted a systematic review and meta-analysis to assess the evidence of the effectiveness of pharmacological and non-pharmacological treatment options in patients with stable non-CF bronchiectasis with a focus on reducing exacerbations.Study selectionMultiple databases were searched through September 2017. Outcomes included the number of patients with exacerbation events, mean number of exacerbations, hospitalisations, mortality, quality of life measures, and safety and adverse effects. Meta-analysis was conducted using the random effects model.Findings30 randomised controlled trials enrolled subjects with non-CF bronchiectasis using different interventions. Moderate-quality evidence supported the effect of long-term antibiotics (≥3 months) on lowering the number of patients experiencing exacerbation events (relative risk 0.77 (95% CI 0.68 to 0.89)), reducing number of exacerbations (incidence rate ratio 0.62 (95% CI 0.49 to 0.78)), improving forced expiratory volume (litre) in the first second (FEV1) (weighted mean difference (WMD); 0.02 (95% CI 0.00 to 0.04)), decreasing sputum purulence scores (numerical scale of 1-8) (WMD −0.90 (95% CI −1.58 to −0.22)) and improving quality of life scores assessed by the St George’s Respiratory Questionnaire (WMD −6.07 (95% CI −10.7 to −1.43)). Bronchospasm increased with inhaled antibiotics while diarrhoea increased particularly with oral macrolide therapy.ConclusionsModerate-quality evidence supports long-term antibiotic therapy for preventing exacerbations in stable non-CF bronchiectasis. However, data about the optimum agent, mode of therapy and length of treatment are limited. There is paucity of high-quality evidence to support the management of stable non-CF bronchiectasis including prevention of exacerbations.

Risk factors leading to pulmonary exacerbation in patients with cystic fibrosis: A systematic review

2021 ◽  
Vol 71 (9) ◽  
Author(s):  
Danish Abdul Aziz ◽  
Syeda Khadija Fatima ◽  
Hasan Nawaz Tahir
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Cystic Fibrosis ◽  
Meta Analysis ◽  
Nutritional Deficiencies ◽  
Pulmonary Exacerbation ◽  
Case Control Studies ◽  
Cross Sectional ◽  
Factors Associated ◽  
Randomised Controlled

Objective: To ascertain major risk factors associated with pulmonary exacerbation and pulmonary function decline in cystic fibrosis. Method: The systematic review was conducted at Aga Khan University, Karachi, in September 2018, and comprised electronic search of PubMed, Ovid, Science Direct and Cumulative Index of Nursing and Allied Health Literature databases of studies conducted from January 1990 to September 2018 which were categorised into 3 sets; 1990-98, 1999-2007 and 2008-18. Studies included for review focussed on articles with pulmonary exacerbation as the health outcome indicator, and had diagnosis of cystic fibrosis as the inclusion criteria, while risk factors were the exposure terms used in the search process. References in bibliographies of the included studies were also systematically searched for relevant documents. Results: Of the 60 studies obtained, 31(51.7%) were selected; 2(6.45%) from 1990-98, 7(22.58%) from 1999-2007 and 22(70.96%) from 2008-18. Overall, 17(54.83%) were cohort studies, 7(22.5%) were cross-sectional studies, 3(9.6%) were case-control studies, 3(9.6%) were randomised controlled trials and 1(3.2%) was systematic review and meta-analysis. In terms of major risk factors, genetic mutations were cited by 4(12.9%) studies, infections and inflammatory biomarkers by 15(48.4%), nutritional deficiencies by 9(29%) and geographical and socioeconomic status by 3(9.6%) studies. Conclusion: Early identification and recognition of risk factors associated with pulmonary exacerbation can have an explicit impact on its management, leading to decreased morbidity and mortality burden in cystic fibrosis cases. Key Words: Pulmonary exacerbation, Cystic fibrosis, Risk factors, Systematic review. Continuous...

scholarly journals Sleep disorders in cystic fibrosis: A systematic review and meta-analysis

2020 ◽  
Vol 51 ◽  
pp. 101279 ◽  
Author(s):  
Joel Reiter ◽  
Alex Gileles-Hillel ◽  
Malena Cohen-Cymberknoh ◽  
Dennis Rosen ◽  
Eitan Kerem ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cystic Fibrosis ◽  
Sleep Disorders ◽  
Meta Analysis

Vitamin D supplementation in patients with cystic fibrosis: A systematic review and meta-analysis

Pancreatology ◽  
2020 ◽  
Vol 20 ◽  
pp. S121
Author(s):  
M. Juhász ◽  
O. Varannai ◽  
D. Németh ◽  
K. Ocskay ◽  
Z. Szakács ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cystic Fibrosis ◽  
Vitamin D ◽  
Meta Analysis ◽  
Vitamin D Supplementation

Efficacy and safety of inhaled antibiotics for chronicpseudomonasinfection in cystic fibrosis: Network meta-analysis

2016 ◽  
Author(s):  
Stuart Elborn ◽  
Anne-Lise Vataire ◽  
Ayako Fukushima ◽  
Samuel Aballéa ◽  
Amine Khemiri ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Inhaled Antibiotics

scholarly journals Endoscopic sinus surgery in patients with cystic fibrosis: a systematic review and meta-analysis of pulmonary function

2012 ◽  
Vol 50 (4) ◽  
pp. 360-369
Author(s):  
K.I. Macdonald ◽  
A. Gipsman ◽  
A. Magit ◽  
M. Fandino ◽  
E. Massoud ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cystic Fibrosis ◽  
Pulmonary Function ◽  
Endoscopic Sinus Surgery ◽  
Meta Analysis ◽  
Pulmonary Function Tests ◽  
Sinus Surgery ◽  
Intravenous Antibiotics

Introduction: The role of endoscopic sinus surgery (ESS) in patients with cystic fibrosis (CF) is not clearly defined. Objective: TO perform a systematic review of subjective and objective outcomes of ESS in CF. Methods: A systematic review was performed using the keywords 'sinusitis,' 'sinus surgery,' 'nasal polyps' and 'cystic fibrosis.' The quality of papers was assessed using the NICE scoring scale. Outcomes included safety, subjective symptoms, objective endoscopy scores, days spent in hospital, courses of antibiotics, and pulmonary function tests (PFTs). Results: Nineteen studies involving 586 patients were included in the review. There were four prospective cohort trials, and three were rated as good quality. There were no major complications attributable to ESS. There was consistent evidence in four cohort studies of improved sinonasal symptoms, including nasal obstruction, facial pain, headaches, rhinorrhea and olfaction. Three studies reported conflicting results in post-operative endoscopy scores. Three studies showed a decrease in days spent in hospital, and two showed a significant decrease in courses of intravenous antibiotics. A recent study, however, did not show a difference in either days spent in hospital or courses of antibiotics. Pulmonary function tests were not improved by ESS in six cohort trials, and one small study found significant improvement. A meta-analysis of FEV1 scores confirmed no significant difference. Conclusion: THE most consistent findings of this review were that ESS in patients with CF is safe, produces symptomatic benefit, and does not consistently improve PFTs. There were more conflicting results with regards to endoscopy scores, days spent in hospital, and courses of intravenous antibiotics. Future prospective studies, utilizing validated quality of life, symptom and endoscopy scales, are needed to further elucidate the role of ESS in the management of chronic rhinosinusitis in CF patients.

Sign in / Sign up

Export Citation Format

Share Document